论文部分内容阅读
目的探究肺炎支原体导致小儿呼吸道感染的发病情况和临床症状,并分析导致小儿呼吸道感染的相关因素。方法 100例支原体肺炎患儿,随机分为观察组和对照组,每组50例。观察组患儿采用阿奇霉素治疗,对照组采用红霉素治疗。观察肺炎支原体导致小儿呼吸道感染的临床症状及特点、两组患儿的治疗效果,并进行对比分析。结果 100例患儿经检测3个月~1岁22例,阳性例数7例,阳性率31.82%,2~3岁患儿31例,阳性例数9例,阳性率29.03%,4~6岁患儿32例,阳性例数9例,阳性率28.13%,7~13岁患儿15例,阳性例数4例,阳性率26.67%,这说明肺炎支原体呼吸道感染的发病群体年龄总体偏小。观察组患儿显效24例(48.0%),有效24例(48.0%),无效2例(4.0%),总有效率为96.0%;对照组患儿显效14例(28.0%),有效25例(50.0%),无效11例(22.0%),总有效率为78.0%。观察组治疗效果显著优于对照组(P<0.05)。结论肺炎支原体可通过呼吸道传播导致小儿呼吸道感染,阿奇霉素对其有显著的临床治疗效果,同时加强小儿身体素质和自身免疫力等,可有效预防小儿呼吸道感染。
Objective To explore the incidence and clinical symptoms of Mycoplasma pneumoniae causing respiratory tract infection in children and to analyze the related factors leading to respiratory tract infection in children. Methods 100 cases of mycoplasma pneumonia children were randomly divided into observation group and control group, 50 cases in each group. The observation group was treated with azithromycin and the control group was treated with erythromycin. To observe the clinical symptoms and characteristics of Mycoplasma pneumoniae causing respiratory tract infection in children, the therapeutic effect of the two groups of children and comparative analysis. Results Totally 100 cases were detected in 22 cases from 3 months to 1 year old, the positive number was 7 cases, the positive rate was 31.82%. There were 31 cases aged 2 to 3 years with 9 positive cases, the positive rate was 29.03% and the positive rate was 4 ~ 6 Year-old children in 32 cases, 9 cases of positive cases, the positive rate was 28.13%, 15 cases of children aged 7 to 13, 4 cases were positive, the positive rate of 26.67%, indicating that the incidence of Mycoplasma pneumoniae respiratory tract infection age groups generally small . In the observation group, 24 cases (48.0%) were effective, 24 cases (48.0%) were effective, 2 cases (4.0%) were ineffective and the total effective rate was 96.0%. In the control group, 14 cases (28.0% (50.0%), ineffective in 11 cases (22.0%), the total effective rate was 78.0%. Observation group was significantly better than the control group (P <0.05). Conclusions Mycoplasma pneumoniae can cause respiratory tract infection in children through respiratory tract. Azithromycin has significant clinical curative effect. At the same time, it can strengthen pediatric physical quality and autoimmunity to prevent respiratory tract infection in children.